Advertisement

Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials

      Abstract

      Background

      This retrospective analysis aimed to determine whether early dose reduction impacts the efficacy of ixabepilone plus capecitabine in women with metastatic breast cancer (MBC).

      Patients and Methods

      In 2 phase III trials, patients (N = 1973) with anthracycline/taxane–pretreated MBC were randomized to receive ixabepilone 40 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily (BID) on days 1 to 14 or single-agent capecitabine 1250 mg/m2 BID on days 1 to 14 of a 3-week course. Because of the similar design and populations, data from trials were pooled to evaluate efficacy of the combination regimen among women who did or did not undergo ixabepilone dose reduction during the first 4 courses. To adjust for bias resulting from selecting patients with inherently better outcome based on longer treatment durations, these analyses were restricted to patients who received ≥ 4 courses of ixabepilone.

      Results

      The pooled cohort included 566 patients with measurable disease who were evaluable for efficacy. Patients who had early dose reduction showed similar objective response rates (ORRs) and progression-free survival (PFS) as did those with no/late dose reduction. ORRs were 62.6% (95% confidence interval [CI], 55.8%-69.0%) and 55.3% (95% CI, 49.9%-60.6%), respectively; median PFS was 7.2 months (95% CI, 6.6-8.0) and 7.0 months (95% CI, 6.5-7.5), respectively (hazard ratio = 0.98; 95% CI, 0.83-1.17).

      Conclusion

      These data suggest that early ixabepilone dose reduction did not affect the overall efficacy of ixabepilone plus capecitabine in patients with MBC who received ≥ 4 courses of treatment. By making appropriate dose reductions, ixabepilone-related toxicities can be minimized while maintaining clinical efficacy.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Bollag D.M.
        • McQueney P.A.
        • Zhu J.
        • et al.
        Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
        Cancer Res. 1995; 55: 2325-2333
        • Michaud L.B.
        The epothilones: how pharmacology relates to clinical utility.
        Ann Pharmacother. 2009; 43: 1294-1309
        • Bode C.J.
        • Gupta Jr, M.L.
        • Reiff E.A.
        • et al.
        Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules.
        Biochemistry. 2002; 41: 3870-3874
        • Lee F.Y.
        • Borzilleri R.
        • Fairchild C.R.
        • et al.
        BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
        Clin Cancer Res. 2001; 7: 1429-1437
        • Lee F.Y.
        • Smykla R.
        • Johnston K.
        • et al.
        Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
        Cancer Chemother Pharmacol. 2009; 63: 201-212
        • Dumontet C.
        • Jordan M.A.
        • Lee F.F.
        Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
        Mol Cancer Ther. 2009; 8: 17-25
        • Low J.A.
        • Wedam S.B.
        • Lee J.J.
        • et al.
        Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
        J Clin Oncol. 2005; 23: 2726-2734
        • Roché H.
        • Yelle L.
        • Cognetti F.
        • et al.
        Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
        J Clin Oncol. 2007; 25: 3415-3420
        • Thomas E.
        • Tabernero J.
        • Fornier M.
        • et al.
        Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
        J Clin Oncol. 2007; 25: 3399-3406
        • Denduluri N.
        • Low J.A.
        • Lee J.J.
        • et al.
        Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
        J Clin Oncol. 2007; 25: 3421-3427
        • Perez E.A.
        • Lerzo G.
        • Pivot X.
        • et al.
        Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
        J Clin Oncol. 2007; 25: 3407-3414
        • Lee F.Y.
        • Camuso G.
        • Castenada X.
        • et al.
        Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.
        J Clin Oncol. 2006; 24 (abstract 12017) (Accessed: April 23, 2012)
        • Bunnell C.
        • Vahdat L.
        • Schwartzberg L.
        • et al.
        Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
        Clin Breast Cancer. 2008; 8: 234-241
        • Thomas E.S.
        • Gomez H.L.
        • Li R.K.
        • et al.
        Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
        J Clin Oncol. 2007; 25: 5210-5217
        • Sparano J.A.
        • Vrdoljak E.
        • Rixe O.
        • et al.
        Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
        J Clin Oncol. 2010; 28: 3256-3263
      1. Ixempra® kit (ixabepilone) for injection: prescribing information.
        Bristol-Myers Squibb, Princeton NJ2010
        • Lechleider R.J.
        • Kaminskas E.
        • Jiang X.
        • et al.
        Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
        Clin Cancer Res. 2008; 14: 4378-4384
        • Hennessy B.T.
        • Gauthier A.M.
        • Michaud L.B.
        • et al.
        Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
        Ann Oncol. 2005; 16: 1289-1296
        • Rossi D.
        • Alessandroni P.
        • Catalano V.
        • et al.
        Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
        Clin Breast Cancer. 2007; 7: 857-860
        • Seidman A.D.
        • Hudis C.A.
        • Albanell J.
        • et al.
        Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
        J Clin Oncol. 1998; 16: 3353-3361